SAGE Sage Therapeutics Inc

Price (delayed)

$71.15

Market cap

$4.16B

P/E Ratio

5.71

Dividend/share

N/A

EPS

$12.46

Enterprise value

$3.28B

Sector: Healthcare
Industry: Biotechnology

Highlights

The net income has surged by 199% year-on-year and by 5% since the previous quarter
SAGE's quick ratio has soared by 163% YoY and by 4.7% QoQ
SAGE's equity has soared by 136% YoY but it is down by 3.3% from the previous quarter

Key stats

What are the main financial stats of SAGE
Market
Shares outstanding
58.48M
Market cap
$4.16B
Enterprise value
$3.28B
Valuations
Price to earnings (P/E)
5.71
Price to book (P/B)
2.07
Price to sales (P/S)
3.73
EV/EBIT
5.15
EV/EBITDA
5.12
EV/Sales
2.95
Earnings
Revenue
$1.11B
EBIT
$637.05M
EBITDA
$641.59M
Free cash flow
$691.82M
Per share
EPS
$12.46
Free cash flow per share
$11.85
Book value per share
$34.31
Revenue per share
$19.08
TBVPS
$35.64
Balance sheet
Total assets
$2.08B
Total liabilities
$77.42M
Debt
$22.72M
Equity
$2B
Working capital
$1.99B
Liquidity
Debt to equity
0.01
Current ratio
33.09
Quick ratio
32.74
Net debt/EBITDA
-1.37
Margins
EBITDA margin
57.6%
Gross margin
99.9%
Net margin
57.2%
Operating margin
56.7%
Efficiency
Return on assets
43.9%
Return on equity
46.6%
Return on invested capital
96%
Return on capital employed
31.6%
Return on sales
57.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SAGE stock price

How has the Sage Therapeutics stock price performed over time
Intraday
2.45%
1 week
-5.22%
1 month
-5.97%
1 year
106.41%
YTD
-17.76%
QTD
-4.94%

Financial performance

How have Sage Therapeutics's revenue and profit performed over time
Revenue
$1.11B
Gross profit
$1.11B
Operating income
$631.34M
Net income
$637.05M
Gross margin
99.9%
Net margin
57.2%
The net income has surged by 199% year-on-year and by 5% since the previous quarter
Sage Therapeutics's operating income has soared by 194% YoY and by 6% from the previous quarter
Sage Therapeutics's operating margin has surged by 101% YoY and by 6% QoQ
The company's net margin has surged by 101% YoY and by 5% QoQ

Growth

What is Sage Therapeutics's growth rate over time

Valuation

What is Sage Therapeutics stock price valuation
P/E
5.71
P/B
2.07
P/S
3.73
EV/EBIT
5.15
EV/EBITDA
5.12
EV/Sales
2.95
Sage Therapeutics's EPS has increased by 7% from the previous quarter
SAGE's equity has soared by 136% YoY but it is down by 3.3% from the previous quarter
The P/B is 66% less than the 5-year quarterly average of 6.0 and 33% less than the last 4 quarters average of 3.0
SAGE's P/S is 98% below its last 4 quarters average of 176.5

Efficiency

How efficient is Sage Therapeutics business performance
SAGE's ROA has soared by 178% year-on-year but it is down by 15% since the previous quarter
Sage Therapeutics's ROE has soared by 174% YoY but it has decreased by 17% from the previous quarter
Sage Therapeutics's ROS has soared by 101% YoY and by 5% from the previous quarter
The ROIC has contracted by 12% from the previous quarter

Dividends

What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SAGE.

Financial health

How did Sage Therapeutics financials performed over time
SAGE's quick ratio has soared by 163% YoY and by 4.7% QoQ
The current ratio has soared by 159% YoY and by 4.8% from the previous quarter
The company's debt is 99% lower than its equity
SAGE's equity has soared by 136% YoY but it is down by 3.3% from the previous quarter
The debt to equity has plunged by 75% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.